CervoMed

Price & Volume

Track all markets on TradingView

Stats

See more
52W Range
$3.51-$11.79
Market Cap
$35.4M
Shares Short
313,488

Financials

See more
Revenue (12 Mos)
$4M
Revenue Growth (YoY)
-99.6%
Gross Profit (12 Mos)
-$17.8M
Diluted EPS
-$2.98

News

See more

Yahoo Finance • last month

CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies

Yahoo Finance • 4 months ago

CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies

Yahoo Finance • 4 months ago

CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)

Yahoo Finance • 5 months ago

CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

About

CEO
Dr. John J. Alam M.D.
CFO
Mr. William Robert Elder J.D.
Address
20 Park Plaza, Boston, MA, United States, 02116
Sector
Healthcare
Industry
Biotechnology
Full-Time Employees
15